{"filing":{"accession_number":"0001171843-26-004120","cik":"0001801198","ticker":"LEGN","company_name":"Legend Biotech Corp","form":"6-K","filing_date":"2026-06-15","report_date":null,"primary_document":"f6k_061426.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1801198/000117184326004120/f6k_061426.htm"},"events":[{"id":12231,"run_id":10795,"accession_number":"0001171843-26-004120","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Legend Biotech announced clinical proof-of-concept data for LB2501, an investigational in vivo CAR-T therapy, presented at EHA 2026. Phase 1 trial results demonstrated 100% ORR and 83.3% CR at dose level 2 with a favorable safety profile, no dose-limiting toxicities, and supporting pharmacokinetic/integration data for the TaVec platform.","company_name":"Legend Biotech Corp","ticker":"LEGN","filing_date":"2026-06-15","form":"6-K","submitted_at":null,"items":[{"id":9031,"accession_number":"0001171843-26-004120","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces clinical proof-of-concept data for LB2501, an investigational in vivo CAR-T therapy, presented at EHA 2026. The disclosure reports Phase 1 trial results showing 100% ORR and 83.3% CR at dose level 2 with a favorable safety profile. While this is a material clinical milestone for a biotech company's pipeline asset, it does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or financial obligation). It is a material operational/clinical development milestone that would affect investor assessment of the company's therapeutic progress and competitive positioning in cell therapy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:26:21.125184+00:00","company_name":"","ticker":null,"filing_date":""},{"id":9032,"accession_number":"0001171843-26-004120","item_number":"EX-99.2","item_title":"exh_992.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This exhibit is a presentation recapping clinical trial data for LB2501, Legend Biotech's in vivo CAR-T therapy candidate, presented at the EHA 2026 conference in June 2026. The presentation discloses Phase 1 trial results showing 100% ORR and 83.3% CR at the higher dose level, favorable safety profile with no dose-limiting toxicities or serious adverse events, and pharmacokinetic/integration data supporting the TaVec platform. While framed as a conference presentation rather than a formal earnings release or regulatory filing, the disclosure of material clinical trial progress and efficacy/safety data for a lead pipeline asset would affect a reasonable investor's assessment of the company's development prospects and de-risks the program. This is classified as operational_other because it represents a material clinical/development milestone for a key product candidate that does not fit the discrete event categories (not an earnings release, not a regulatory approval, not a material impairment or covenant breach).","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:26:21.125184+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9031,"accession_number":"0001171843-26-004120","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces clinical proof-of-concept data for LB2501, an investigational in vivo CAR-T therapy, presented at EHA 2026. The disclosure reports Phase 1 trial results showing 100% ORR and 83.3% CR at dose level 2 with a favorable safety profile. While this is a material clinical milestone for a biotech company's pipeline asset, it does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or financial obligation). It is a material operational/clinical development milestone that would affect investor assessment of the company's therapeutic progress and competitive positioning in cell therapy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:26:21.125184+00:00","company_name":"Legend Biotech Corp","ticker":"LEGN","filing_date":"2026-06-15"},{"id":9032,"accession_number":"0001171843-26-004120","item_number":"EX-99.2","item_title":"exh_992.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This exhibit is a presentation recapping clinical trial data for LB2501, Legend Biotech's in vivo CAR-T therapy candidate, presented at the EHA 2026 conference in June 2026. The presentation discloses Phase 1 trial results showing 100% ORR and 83.3% CR at the higher dose level, favorable safety profile with no dose-limiting toxicities or serious adverse events, and pharmacokinetic/integration data supporting the TaVec platform. While framed as a conference presentation rather than a formal earnings release or regulatory filing, the disclosure of material clinical trial progress and efficacy/safety data for a lead pipeline asset would affect a reasonable investor's assessment of the company's development prospects and de-risks the program. This is classified as operational_other because it represents a material clinical/development milestone for a key product candidate that does not fit the discrete event categories (not an earnings release, not a regulatory approval, not a material impairment or covenant breach).","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:26:21.125184+00:00","company_name":"Legend Biotech Corp","ticker":"LEGN","filing_date":"2026-06-15"}]}